B Program Ceiling Price News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from B program ceiling price. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In B Program Ceiling Price Today - Breaking & Trending Today

HRSA accuses Merck of denying 340B discounts

Late last week, the Health and Resources Services Administration (HRSA) sent a letter to Merck warning that it may be dealt monetary penalties for allegedly refusing to give 340B discounts to covered entities. HRSA first contacted Merck about the matter in May, when the agency instructed the biopharmaceutical company to comply with 340B statutory obligations, and immediately ....

Shana Novak Getty , Eli Lilly , Resources Services Administration , Office Of Inspector , Human Services , American Hospital Association , Office Of The Inspector , Boehringer Ingelheim , Us Supreme Court , Department Of Health , B Program Ceiling Price , Novo Nordisk , Inspector General , Program Ceiling Price , Civil Monetary Penalties Final Rule , Prospective Payment System ,

HRSA orders Boehringer Ingelheim to comply with 340B drug pricing

The Health Resources andServices Administration (HRSA) has sent a letter to Boehringer Ingelheim ordering the pharmaceutical company to comply with federal requirements under the 340B drug pricing program. HRSA informed the company that its August 1 policy cutting off discounted pricing to hospitals on drugs dispensed at community-based pharmacies is unlawful. The agency ....

Michelle Herzog , Derekl Asay , Eli Lilly , Maureen Testoni , Company Lilly , B Health , Health Resources , Us Department Of Health , Human Services , Office Of The Inspector , Boehringer Ingelheim , Office Of Pharmacy Affairs , Services Administration , Department Of Health , B Program Ceiling Price , Novo Nordisk , Government Strategy , Pharmacy Affairs , Inspector General , Program Ceiling Price , Civil Monetary Penalties Final Rule , United Therapeutics , Health President ,

Six drugmakers in violation of 340B statute, says HRSA

Photo: Jeff Lagasse/Healthcare Finance News
Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter sent to the drugmakers this week from the Health Resources and Services Administration.
The HRSA maintained that the drug manufacturers in question – AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi and United Therapeutics – placed restrictions on the 340B program for hospitals that dispense drugs through contract pharmacies, and these restrictions resulted in overcharges, which are in direct violation of the statute.
Various actions from the manufacturers limited beneficiaries access to discounted drugs available through the 340B program, HRSA said. Some, for instance, stopped providing the 340B ceiling price on products sold to covered entities and dispensed through contract pharmacies. Others limited sales by requiri ....

United States , Alex Azar , Xavier Becerra , Donald Trump , Diana Espinosa , Eli Lilly , Ryan White , Maureen Testoni , Us Department Of Health , Human Services , B Health , Health Resources , American Hospital Association , Trump Administration , Us Court , Biden Administration , B Program , Department Of Health , B Program Ceiling Price , Novo Nordisk , Healthcare Finance News , Program Ceiling Price , Civil Monetary Penalties , Administrator Diana Espinosa , President Donald , Columbia Circuit ,